Format

Send to

Choose Destination
Mol Oncol. 2010 Jun;4(3):284-300. doi: 10.1016/j.molonc.2010.04.005. Epub 2010 Apr 24.

Molecular basis for therapy resistance.

Author information

1
Section of Oncology, Institute of Medicine, University of Bergen, Norway. per.lonning@helse-bergen.no

Abstract

Chemoresistance remains the main reason for therapeutic failure in breast cancer as well as most other solid tumours. While gene expression profiles related to prognosis have been developed, so far use of such signatures as well as single markers has been of limited value predicting drug resistance. Novel technologies, in particular with regard to high through-put sequencing holds great promises for future identification of the key "driver" mechanisms guiding chemosensitivity versus resistance in breast cancer as well as other malignant conditions.

PMID:
20466604
PMCID:
PMC5527935
DOI:
10.1016/j.molonc.2010.04.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center